

Title (en)  
SPOT-ON FORMULATION USEFUL FOR COSMETOLOGY AND DERMATOLOGY

Title (de)  
SPOT-ON-FORMULIERUNG ZUR KOSMETISCHEN UND DERMATOLOGISCHEN VERWENDUNG

Title (fr)  
FORMULATION DE TYPE SPOT-ON UTILE EN COSMETOLOGIE ET EN DERMATOLOGIE

Publication  
**EP 1748758 A1 20070207 (FR)**

Application  
**EP 05770872 A 20050512**

Priority

- FR 2005001188 W 20050512
- FR 0405136 A 20040512

Abstract (en)  
[origin: WO2005115335A1] The invention relates to a novel formulation useful for cosmetology and dermatology by using the storage capacity of sebaceous glands. The inventive spot-on formulation contains an active lipophilic principle selected from the vitamin A and E, a lipophilic antioxidant agent, ceramides or sphingoid bases and steroid hormones associated with one or several fatty acids unsaturated in C4-C26 and a liquid vehicle having sebaceous tropism. The inventive formulation is usable for local topical administration of the active lipophilic principles.

IPC 8 full level  
**A61K 9/08** (2006.01); **A61K 8/67** (2006.01); **A61K 9/00** (2006.01); **A61K 9/107** (2006.01); **A61K 31/133** (2006.01); **A61K 31/20** (2006.01); **A61K 31/201** (2006.01); **A61K 31/202** (2006.01); **A61K 31/203** (2006.01); **A61K 31/355** (2006.01); **A61K 47/12** (2006.01); **A61Q 5/00** (2006.01); **A61Q 17/04** (2006.01); **A61Q 19/00** (2006.01)

CPC (source: EP KR US)  
**A61K 8/671** (2013.01 - EP US); **A61K 8/678** (2013.01 - EP US); **A61K 9/08** (2013.01 - EP US); **A61K 9/107** (2013.01 - EP US); **A61K 31/133** (2013.01 - EP KR US); **A61K 31/20** (2013.01 - EP US); **A61K 31/201** (2013.01 - EP US); **A61K 31/202** (2013.01 - EP US); **A61K 31/203** (2013.01 - EP US); **A61K 31/35** (2013.01 - KR); **A61K 31/355** (2013.01 - EP US); **A61K 47/12** (2013.01 - EP US); **A61P 17/00** (2017.12 - EP); **A61P 17/08** (2017.12 - EP); **A61P 17/10** (2017.12 - EP); **A61P 17/14** (2017.12 - EP); **A61Q 17/04** (2013.01 - KR); **A61Q 19/00** (2013.01 - EP KR US); **A61K 2800/28** (2013.01 - EP US); **A61Q 5/12** (2013.01 - EP US); **A61Q 17/04** (2013.01 - EP US); **A61Q 19/08** (2013.01 - EP US)

Citation (search report)  
See references of WO 2005115335A1

Citation (examination)

- WO 2004064841 A1 20040805 - SHIRE HOLDING AG [CH], et al
- WO 9003163 A1 19900405 - UNIV FLORIDA [US]
- EP 0499662 A1 19920826 - WARNER LAMBERT CO [US]
- DE 4407742 C1 19950622 - HEXAL PHARMA GMBH [DE]
- US 6248805 B1 20010619 - NGUYEN KHE C [US], et al
- WO 9524187 A1 19950914 - HEXAL PHARMA GMBH [DE], et al
- AU 3025889 A 19890914 - WARNER LAMBERT CO
- WO 9850023 A1 19981112 - KLIGMAN DOUGLAS E [US], et al

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2005115335 A1 20051208**; BR PI0510806 A 20071106; CA 2562565 A1 20051208; EP 1748758 A1 20070207; FR 2870125 A1 20051118; FR 2870125 B1 20100326; IL 178889 A0 20070308; JP 2007537214 A 20071220; KR 20070026580 A 20070308; US 2009010968 A1 20090108

DOCDB simple family (application)  
**FR 2005001188 W 20050512**; BR PI0510806 A 20050512; CA 2562565 A 20050512; EP 05770872 A 20050512; FR 0405136 A 20040512; IL 17888906 A 20061026; JP 2007512289 A 20050512; KR 20067026165 A 20061212; US 59633405 A 20050512